Overview

A Study of JNJ-73763989 in Adult Participants With Renal Impairment

Status:
Recruiting
Trial end date:
2022-02-02
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the pharmacokinetics (PK) of a single subcutaneous (SC) dose of JNJ-73763989 in adult participants with renal impairment compared with healthy participants with normal renal function.
Phase:
Phase 1
Details
Lead Sponsor:
Janssen Research & Development, LLC